In August 2025, a groundbreaking announcement was made regarding a collaboration between the two industry leaders named Tempus and Genialis to develop RNA based biomarkers and algorithm. This strategic partnership between the two brings together the expertise of both companies to revolutionize the field of precise medicines.
The collaboration aims to harness the power of RNA-based biomarkers to develop innovative algorithm that can accurately diagnose and monitor complex diseases. By leveraging the unique strength of both companies, the partnership seeks to create a new generation of precision medicine tools. These tools will help in improving the patients outcomes and transform the healthcare landscape.
The development of RNA-based biomarkers and algorithm has the potential to revolutionize the way diseases are diagnosed and treated. By providing clinicians with more accurate and reliable tools, this technology can enable intervention, better patients outcome, and more effective treatment. As the collaboration progresses, the companies are expected to make significant advancement in the field. It will pave the way for new era of precision medicines.
As per the Coherent Market Insights report, the global biomarkers industry is set to expand at a CAGR of 13.6% from 2022 to 2030. In 2030, revenue generated from the sales will reach at US$ 54.19 billion from US$ 55.59 Billion in 2022. Increasing rate of research and development activities will improve biomarkers effectiveness that is based on test and assays.
Moreover, increasing rate of inorganic growth activities including collaboration among key industry players is poised to drive demand in the global industry. Another factor boosting growth is increasing importance of companion diagnostics and increasing prevalence of cancer.
Based on the region, North America is poised to hold leading position in the global biomarkers industry. This is owing to increasing product designation by the regulatory activities. Development of novel drug therapies and increasing clinical trials will help in contributing regions growth. This is followed by Asia Pacific that is driven by the rising research and funding in the field of novel therapies.
Biomarkers plays an important role in the selection of targeted therapies that address molecular characteristics of patient tumor. For instance, these specific mutation and alteration in cancer cell are susceptible to inhibition by targeted drugs.
Increasing prevalence of fatal disease in past few years including cardiovascular diseases, diabetes, cancer, and other chronic diseases. The major factors that will lead to increasing the prevalence is changing lifestyle.
Leading companies in the industry is focusing on introducing programs that increase commercialization of biomarker-based products. The major strategies adopted by the key players is expanding their market portfolio and diverse technology and innovative product to its customers. These strategies are basically adopted by the companies to attract more customers.
